Primary tabs

Novel Therapy Targeting the Cryptosporidium Virus

Nigel Yarlett of Pace University in the U.S. will determine whether a virus that infects the intestinal parasite Cryptosporidium is a valuable target for developing drugs against the associated chronic diarrheal disease, which causes substantial morbidity and mortality in young children in low-resource settings. The double-stranded RNA Cryspoviruses are not harmful to the parasite, and instead likely enhance the parasite's ability to infect and harm humans. They will create a continuous in vitro culture of the Cryptosporidium parasite carrying viruses that will be genetically modified to fluoresce for easy monitoring, and also use RNA interference to generate a parasite strain that does not contain any viruses. These tools will be used to study the role of the virus in the growth and development of the parasite. Ultimately, a drug targeting the virus, rather than the parasite itself, may be less toxic to the good bacteria in the human gut, and less likely to drive the development of drug resistance.

Display Title (Formatted)

Novel Therapy Targeting the Cryptosporidium Virus

Grant ID
OPP1170819
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Principal Investigator
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False